Mercury (element)

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2

Retrieved on: 
Wednesday, April 10, 2024

OMNI facilitates a unique implant-free, ab interno procedure that comprehensively addresses the three primary areas of resistance in the conventional outflow pathway.

Key Points: 
  • OMNI facilitates a unique implant-free, ab interno procedure that comprehensively addresses the three primary areas of resistance in the conventional outflow pathway.
  • OMNI technology has been cleared by the FDA for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
  • The primary treatment goal for the high baseline IOP group (> 18mmHg) was IOP reduction, with a secondary goal to reduce medication burden.
  • The primary treatment goal for the low baseline IOP group (

Michaela School prayer ban: allowing for religious diversity in education is a tradition in England

Retrieved on: 
Thursday, April 25, 2024

A Muslim student at Michaela School in London has lost her High Court challenge against the school’s ban on prayer rituals.

Key Points: 
  • A Muslim student at Michaela School in London has lost her High Court challenge against the school’s ban on prayer rituals.
  • The school argued that the ban was put in place to avoid prayers “undermining inclusion”.
  • But permitting religious diversity is a tradition in education in England.

Understanding secularism

  • Michaela School has two-week holidays over the Christmas and Easter periods, and names them for these Christian festivals.
  • The school week is Monday to Friday, which does not impinge upon the Christian day of rest.
  • This is a version of secularism that benefits the members of one religion but not another.
  • The state’s burgeoning financial involvement in education was accompanied by a pluralist approach to minority religions and denominations.

Matters of conscience

  • It contained a conscience clause, allowing non-Anglican parents to withdraw their children from religious instruction.
  • The end of Empire and the 1948 Nationality Act brought migrants to Britain from the Indian subcontinent.
  • By the mid-1960s, Muslim children began to appear in schools in sufficient numbers that they were able to campaign collectively for the accommodation of their needs.
  • And since the 1960s local education authorities and schools have accommodated Muslim needs within the same framework as those of Jews and Catholics.


Helen Carr does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session

Retrieved on: 
Friday, April 5, 2024

The updated data set presented at ACC in Atlanta focuses on 46 patients from FOREST-HCM that had completed 48 weeks of follow-up at the time of the current interim analysis.

Key Points: 
  • The updated data set presented at ACC in Atlanta focuses on 46 patients from FOREST-HCM that had completed 48 weeks of follow-up at the time of the current interim analysis.
  • At Week 48, 75% of these patients were receiving the 15 mg or 20 mg dose of aficamten.
  • Additionally, there were significant improvements in NT-proBNP, a biomarker of cardiac wall stress, with an average decrease of 63% from baseline to week 48 (p
  • There was a modest reduction in left ventricular ejection fraction (LVEF) from baseline to Week 48 (mean change from baseline (SD) = -5.1 mg (5.9), p

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session

Retrieved on: 
Friday, April 5, 2024

The updated data set presented at ACC in Atlanta focuses on 46 patients from FOREST-HCM that had completed 48 weeks of follow-up at the time of the current interim analysis.

Key Points: 
  • The updated data set presented at ACC in Atlanta focuses on 46 patients from FOREST-HCM that had completed 48 weeks of follow-up at the time of the current interim analysis.
  • At Week 48, 75% of these patients were receiving the 15 mg or 20 mg dose of aficamten.
  • Additionally, there were significant improvements in NT-proBNP, a biomarker of cardiac wall stress, with an average decrease of 63% from baseline to week 48 (p
  • There was a modest reduction in left ventricular ejection fraction (LVEF) from baseline to Week 48 (mean change from baseline (SD) = -5.1 mg (5.9), p

Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting

Retrieved on: 
Tuesday, March 5, 2024

“We are proud to have presented data on our lead product candidate NCX 470 in glaucoma to the scientific community at the prestigious AGS meeting.

Key Points: 
  • “We are proud to have presented data on our lead product candidate NCX 470 in glaucoma to the scientific community at the prestigious AGS meeting.
  • The data provide further evidence of the efficacy of NCX 470, and its robust intraocular pressure lowering effect, reinforcing the positive results we have seen in the first Phase 3 trial, Mont Blanc.
  • Furthermore, NCX 470 provided consistent IOP reduction across the spectrum of baseline IOPs while latanoprost IOP reduction was baseline IOP-dependent.
  • In a pre-planned analysis, we tested whether being on previous IOP lowering medications had an impact on the IOP lowering of NCX 470.

Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years

Retrieved on: 
Monday, February 26, 2024

“These new long-term follow up data demonstrate AVIM therapy’s ability to drive a substantial and sustained reduction in 24-hour ambulatory systolic blood pressure, the gold standard, and most accurate measure of hypertension.

Key Points: 
  • “These new long-term follow up data demonstrate AVIM therapy’s ability to drive a substantial and sustained reduction in 24-hour ambulatory systolic blood pressure, the gold standard, and most accurate measure of hypertension.
  • Each patient’s aSBP was measured an average of 3.6 (±0.6) years following original initiation of AVIM therapy.
  • AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure.
  • Orchestra BioMed and Medtronic plc (NYSE: MDT) (“Medtronic”) formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022.

GRAND CANYON UNIVERSITY HONORS LEADERS WITH THE FOURTH ANNUAL COLANGELO SERVANT LEADERSHIP AWARDS

Retrieved on: 
Wednesday, February 14, 2024

PHOENIX, Feb. 14, 2024 /PRNewswire/ -- Grand Canyon University honored four committed leaders who embody the ideal for which Jerry Colangelo is best known – servant leadership – during the fourth annual Colangelo Servant Leadership Awards on Wednesday morning.

Key Points: 
  • PHOENIX, Feb. 14, 2024 /PRNewswire/ -- Grand Canyon University honored four committed leaders who embody the ideal for which Jerry Colangelo is best known – servant leadership – during the fourth annual Colangelo Servant Leadership Awards on Wednesday morning.
  • The Colangelo Servant Leadership Awards, presented by Freeport-McMoRan, are named after one of Arizona's most notable business and sports icons who is also the namesake of GCU's Colangelo College of Business (CCOB).
  • When we pick recipients for The Colangelo Servant Leadership Awards, we are looking for those business leaders in our community who really represent that type of leadership," said Dean of GCU's Colangelo College of Business John Kaites.
  • The 2023 Colangelo Servant Leadership recipients were Don Cardon, Tommy Espinoza, Dawn Grove and Steve Zabilski.

HealthSnap and UnityPoint Health Announce Systemwide Virtual Care Management Partnership Expansion

Retrieved on: 
Thursday, January 11, 2024

MIAMI, Jan. 11, 2024 /PRNewswire/ -- HealthSnap, a leading virtual care management platform, and UnityPoint Health, the nation's fifth-largest non-denominational health system, announced today the continued expansion of their partnership, which went live in January 2023. As one of the nation's most integrated health systems, UnityPoint Health serves nearly 8 million patient visits per year throughout Iowa, western Illinois, and southern Wisconsin.

Key Points: 
  • MIAMI, Jan. 11, 2024 /PRNewswire/ -- HealthSnap , a leading virtual care management platform, and UnityPoint Health , the nation's fifth-largest non-denominational health system, announced today the continued expansion of their partnership, which went live in January 2023.
  • The partnership, which includes both HealthSnap's Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) programs has successfully been delivered to over 25,000 UnityPoint Health patients across Iowa and Illinois.
  • "UnityPoint Health is focused on providing easier and more personalized care for all those we serve, and by partnering with HealthSnap, we are able to seamlessly implement virtual care management programs for our patients living with chronic conditions," said Patricia Newland, MD, President of UnityPoint Clinic.
  • "We are thrilled to be expanding our partnership with UnityPoint Health and integrating our virtual care management programs across their patient population," said HealthSnap Co-Founder & CEO, Samson Magid.

Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

Retrieved on: 
Thursday, December 14, 2023

“The FDA approval of iDose TR represents a significant milestone for Glaukos following an extensive pioneering journey since the inception of the original idea nearly 15 years ago.

Key Points: 
  • “The FDA approval of iDose TR represents a significant milestone for Glaukos following an extensive pioneering journey since the inception of the original idea nearly 15 years ago.
  • The FDA approval and Phase 3 data referenced below is for the slow-release iDose TR model, consistent with the company’s NDA submission and commercialization plans.
  • Alongside the iDose TR approval announcement, Glaukos is proud to introduce the iDose Your Dose Initiative.
  • ET (5:30 a.m. PT) to discuss the FDA approval of iDose TR.

Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

Retrieved on: 
Thursday, November 16, 2023

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT (xanomeline-trospium) on 24-hour ambulatory blood pressure in adults with schizophrenia demonstrating that KarXT was not associated with increases in blood pressure.

Key Points: 
  • Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced positive results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT (xanomeline-trospium) on 24-hour ambulatory blood pressure in adults with schizophrenia demonstrating that KarXT was not associated with increases in blood pressure.
  • The primary endpoint in the trial was the change from baseline at week 8 in 24-hour average ambulatory systolic blood pressure.
  • In the trial, KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of -0.59 mmHg.
  • Additional vital sign measures collected in the trial, including 24-hour average diastolic blood pressure and heart rate, were consistent with prior trials of KarXT in schizophrenia.